NEW YORK, May 15, 2019 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc., (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, is pleased to announce the acceptance of three poster presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting to be held May 31 through June 4, 2019 in Chicago, Illinois. Two of these presentations were submitted by Memorial Sloan Kettering Cancer Center (MSK) in New York and one was submitted by Hospital Sant Joan de Déu, Barcelona, Spain (HSJ) together with MSK.
These abstracts are publicly available online at https://meetinglibrary.asco.org/.
The omburtamab abstract includes a poster presentation of
The naxitamab abstracts include poster presentations of